Zentis
For design-conscious travelers seeking quiet sophistication, this stay delivers cosmopolitan style with Japanese sensibilities—without the hefty price tag.
Set the scene
Zentis Osaka attracts a globe-trotting mix of creative professionals and discerning leisure travelers who appreciate thoughtful design over flashy amenities. In the light-filled lobby lounge, expect to spot digital nomads tapping away at their laptops while a family of four ascends the distinctive limestone staircase that leads toward Upstairz restaurant. A double-sided fireplace and floor-to-ceiling windows connect the indoor space with the green-lined outdoor terrace.
The backstory
Palace Hotel Group's debut Zentis property opened in 2020 as Osaka's first Design Hotels member, occupying a 16-story contemporary tower in the Dojimahama business district. Internationally renowned UK firm Tara Bernerd & Partners crafted the interiors with an industrial-chic aesthetic that embraces Japanese minimalism. The location places guests at the confluence of the riverside business area and the entertainment district of Kitashinchi, with the cultural treasures of Nakanoshima island just a 10-minute stroll away.
The rooms
Zentis succeeds where many urban hotels stumble: creating intelligently designed accommodations that feel comfortable rather than cramped. The 169 studio rooms (most of the property's 212 total) span a generous 270 square feet with walk-in showers featuring sage green tiles. The soft, earthy palette—Irish wool throws, woven rugs, blond wood furnishings—creates warmth against the cool-toned gray and sand color scheme, while calligraphic brushstroke artwork above beds injects personality. Local craftsmanship shines with ceramic bedside tables by artisans from Shiga Prefecture and midcentury-inspired wooden chairs made in Japan.
Bath enthusiasts should upgrade to corner studios, which add separate soaking tubs to the shower setup. Book the eighth floor or higher for city views that include distant glimpses of Osaka Castle's rooftop.
Food and drink
Executive chef Shinya Otsuchihashi brings Michelin-pedigreed experience from Tokyo's Craftale to Upstairz, the hotel's all-day dining on the second floor. The 116-seat space encompasses an open-kitchen dining room, lounge area, and covered outdoor terrace. The menu draws upon Japanese and French influences, emphasizing local, seasonal ingredients—think a melange of vegetables, each in a different preparation, and deep-sea shrimp beneath a saffron-scented sabayon. Don't miss the excellent Japanese breakfast in the morning. The real standout, however, is Upstairz bar, where award-winning head bartender Norihiko Furuse has created a menu of delectable cocktails, like a velvety nightcap of Oloroso sherry, Mancino vermouth, and bitters—reason enough to visit even if you're not staying at the hotel.
The spa
While there is no spa on property, there is a 24-hour fitness center outfitted with Life Fitness equipment.
The neighborhood
The Dojimahama location strikes a balance between business convenience and cultural exploration. Osaka Station is just five minutes away by taxi, while the nearby museums and galleries of Nakanoshima provide a peaceful respite from urban energy. The adjacent Kita-shinchi entertainment district offers everything from intimate izakayas to upscale dining. An interactive map lists the hotel's own curated recommendations for exploring the city's food scene.
The service
Staff combine polished professionalism with Osaka-style warmth.
Eco effort
Sustainability initiatives include LED lighting, water-saving toilets, refillable dispenser bottles for bath amenities, and an eco-card system that allows guests to opt out of daily linen changes to conserve water and energy.
For families
Children under the age of 12 stay for free when sharing a bed with their parents. For larger groups, adjoining corner and studio king rooms can be connected via a shared door, creating a practical two-room suite. Kids' amenities include mini-toothbrushes and slippers.
Accessibility
The hotel offers comprehensive accessibility with four ADA-compliant rooms, step-free entry to all accommodations, and wheelchair-accessible facilities throughout. All doorways accommodate wheelchair users, while the main entrance provides level access from the sidewalk.
Anything left to mention?
On the second floor, the hotel's unique Room 001 is a multi-purpose chill-out space. In the back corner, The Shoeshine Guild buffs footwear with Jack Daniels–infused polish while a fragrance bar offers perfumes and colognes selected by aroma advisors. Cozy seating areas invite guests to linger over complimentary Nespresso and curated reading materials—from photography books to Japanese manga—while self-service laundry facilities use natural detergent.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Sony and Nintendo's Tariff Resilience Makes Japan a New Safe Haven
Welcome to Tech In Depth, our daily newsletter about the business of tech from Bloomberg's journalists around the world. Today, Vlad Savov looks at the outburst of optimism about big tech names in Japan, where gaming and AI are fueling stocks to new highs. Blue Apron's pivot: Blue Apron, a pioneer in meal kits, is axing its subscription plan in favor of an a-la-carte model, and is now offering some microwavable options in a bid to win over users with less time to cook.
Associated Press
3 hours ago
- Associated Press
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
NEW YORK & TOKYO--(BUSINESS WIRE)--Aug 12, 2025-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, 'Astellas') today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV ™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA ™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for or declined cisplatin-based chemotherapy. This press release features multimedia. View the full release here: At the first interim efficacy analysis, the trial demonstrated a clinically meaningful and statistically significant improvement in event-free survival (EFS), the study's primary endpoint, and overall survival (OS), a key secondary endpoint, with neoadjuvant and adjuvant PADCEV plus KEYTRUDA versus surgery alone. An additional secondary endpoint of pathologic complete response (pCR) rate was also met. The trial is continuing to evaluate the secondary EFS, OS and pCR rate endpoints for neoadjuvant and adjuvant KEYTRUDA versus surgery alone as they continue to mature. The safety profiles for PADCEV plus KEYTRUDA and KEYTRUDA monotherapy were consistent with the known profiles of each treatment regimen. Bladder cancer is the ninth most common cancer worldwide, diagnosed in more than 614,000 patients each year globally. i MIBC represents approximately 30% of all bladder cancer cases. ii The standard treatment for patients with MIBC is neoadjuvant cisplatin-based chemotherapy followed by surgery, which has been shown to prolong survival. ii However, up to half of patients with MIBC are not eligible to receive cisplatin and face limited treatment options, typically undergoing surgery alone. iii Results will be submitted for presentation at an upcoming medical congress and will be discussed with global health authorities for potential regulatory filings. Neoadjuvant and adjuvant PADCEV plus KEYTRUDA is also being evaluated in cisplatin-eligible patients with MIBC in the EV-304 Phase 3 clinical trial (also known as KEYNOTE-B15). The primary endpoint of this trial is EFS between arm C versus arm B, defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes radical cystectomy (RC) surgery or failure to undergo RC surgery in participants with residual disease, gross residual disease left behind at the time of surgery, local or distant recurrence as assessed by imaging and/or biopsy or death due to any cause. Key secondary endpoints include OS and pCR rate between arm C and arm B, as well as EFS, OS and pCR rate between arm A and arm B. iv For more information on the global EV-303 trial, go to PADCEV plus KEYTRUDA is approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) regardless of cisplatin eligibility in the United States, the European Union, Japan and a number of other countries around the world. PADCEV is also approved as a single agent for the treatment of adult patients with la/mUC who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. vi PADCEV ® (enfortumab vedotin-ejfv) U.S. Indication & Important Safety Information BOXED WARNING: SERIOUS SKIN REACTIONS PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or mUC who: PADCEV Important Safety Information Warnings and Precautions Skin reactions Severe cutaneous adverse reactions, including fatal cases of SJS or TEN occurred in patients treated with PADCEV. SJS and TEN occurred predominantly during the first cycle of treatment but may occur later. Skin reactions occurred in 70% (all grades) of the 564 patients treated with PADCEV in combination with pembrolizumab in clinical trials. When PADCEV was given in combination with pembrolizumab, the incidence of skin reactions, including severe events, occurred at a higher rate compared to PADCEV as a single agent. The majority of the skin reactions that occurred with combination therapy included maculo-papular rash, macular rash and papular rash. Grade 3-4 skin reactions occurred in 17% of patients (Grade 3: 16%, Grade 4: 1%), including maculo-papular rash, bullous dermatitis, dermatitis, exfoliative dermatitis, pemphigoid, rash, erythematous rash, macular rash, and papular rash. A fatal reaction of bullous dermatitis occurred in one patient (0.2%). The median time to onset of severe skin reactions was 1.7 months (range: 0.1 to 17.2 months). Skin reactions led to discontinuation of PADCEV in 6% of patients. Skin reactions occurred in 58% (all grades) of the 720 patients treated with PADCEV as a single agent in clinical trials. Twenty-three percent (23%) of patients had maculo-papular rash and 34% had pruritus. Grade 3-4 skin reactions occurred in 14% of patients, including maculo-papular rash, erythematous rash, rash or drug eruption, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, and palmar-plantar erythrodysesthesia. The median time to onset of severe skin reactions was 0.6 months (range: 0.1 to 8 months). Among patients experiencing a skin reaction leading to dose interruption who then restarted PADCEV (n=75), 24% of patients restarting at the same dose and 24% of patients restarting at a reduced dose experienced recurrent severe skin reactions. Skin reactions led to discontinuation of PADCEV in 3.1% of patients. Monitor patients closely throughout treatment for skin reactions. Consider topical corticosteroids and antihistamines, as clinically indicated. For persistent or recurrent Grade 2 skin reactions, consider withholding PADCEV until Grade ≤1. Withhold PADCEV and refer for specialized care for suspected SJS, TEN or for Grade 3 skin reactions. Permanently discontinue PADCEV in patients with confirmed SJS or TEN; or Grade 4 or recurrent Grade 3 skin reactions. Hyperglycemia and diabetic ketoacidosis (DKA), including fatal events, occurred in patients with and without pre-existing diabetes mellitus, treated with PADCEV. Patients with baseline hemoglobin A1C ≥8% were excluded from clinical trials. In clinical trials of PADCEV as a single agent, 17% of the 720 patients treated with PADCEV developed hyperglycemia of any grade; 7% of patients developed Grade 3-4 hyperglycemia (Grade 3: 6.5%, Grade 4: 0.6%). Fatal events of hyperglycemia and DKA occurred in one patient each (0.1%). The incidence of Grade 3-4 hyperglycemia increased consistently in patients with higher body mass index and in patients with higher baseline A1C. The median time to onset of hyperglycemia was 0.5 months (range: 0 to 20 months). Hyperglycemia led to discontinuation of PADCEV in 0.7% of patients. Five percent (5%) of patients required initiation of insulin therapy for treatment of hyperglycemia. Of the patients who initiated insulin therapy for treatment of hyperglycemia, 66% (23/35) discontinued insulin at the time of last evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV. Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV. When PADCEV was given in combination with pembrolizumab, 10% of the 564 patients treated with combination therapy had pneumonitis/ILD of any grade and 4% had Grade 3-4. A fatal event of pneumonitis/ILD occurred in two patients (0.4%). The incidence of pneumonitis/ILD, including severe events, occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of any grade pneumonitis/ILD was 4 months (range: 0.3 to 26 months). In clinical trials of PADCEV as a single agent, 3% of the 720 patients treated with PADCEV had pneumonitis/ILD of any grade and 0.8% had Grade 3-4. The median time to onset of any grade pneumonitis/ILD was 2.9 months (range: 0.6 to 6 months). Monitor patients for signs and symptoms indicative of pneumonitis/ILD such as hypoxia, cough, dyspnea or interstitial infiltrates on radiologic exams. Evaluate and exclude infectious, neoplastic and other causes for such signs and symptoms through appropriate investigations. Withhold PADCEV for patients who develop Grade 2 pneumonitis/ILD and consider dose reduction. Permanently discontinue PADCEV in all patients with Grade 3 or 4 pneumonitis/ILD. Peripheral neuropathy (PN) When PADCEV was given in combination with pembrolizumab, 67% of the 564 patients treated with combination therapy had PN of any grade, 36% had Grade 2 neuropathy, and 7% had Grade 3 neuropathy. The incidence of PN occurred at a higher rate when PADCEV was given in combination with pembrolizumab compared to PADCEV as a single agent. The median time to onset of Grade ≥2 PN was 6 months (range: 0.3 to 25 months). PN occurred in 53% of the 720 patients treated with PADCEV as a single agent in clinical trials including 38% with sensory neuropathy, 8% with muscular weakness and 7% with motor neuropathy. Thirty percent of patients experienced Grade 2 reactions and 5% experienced Grade 3-4 reactions. PN occurred in patients treated with PADCEV with or without preexisting PN. The median time to onset of Grade ≥2 PN was 4.9 months (range: 0.1 to 20 months). Neuropathy led to treatment discontinuation in 6% of patients. Monitor patients for symptoms of new or worsening PN and consider dose interruption or dose reduction of PADCEV when PN occurs. Permanently discontinue PADCEV in patients who develop Grade ≥3 PN. Ocular disorders were reported in 40% of the 384 patients treated with PADCEV as a single agent in clinical trials in which ophthalmologic exams were scheduled. The majority of these events involved the cornea and included events associated with dry eye such as keratitis, blurred vision, increased lacrimation, conjunctivitis, limbal stem cell deficiency, and keratopathy. Dry eye symptoms occurred in 30% of patients, and blurred vision occurred in 10% of patients, during treatment with PADCEV. The median time to onset to symptomatic ocular disorder was 1.7 months (range: 0 to 30.6 months). Monitor patients for ocular disorders. Consider artificial tears for prophylaxis of dry eyes and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Consider treatment with ophthalmic topical steroids, if indicated after an ophthalmic exam. Consider dose interruption or dose reduction of PADCEV for symptomatic ocular disorders. Infusion site extravasation Skin and soft tissue reactions secondary to extravasation have been observed after administration of PADCEV. Of the 720 patients treated with PADCEV as a single agent in clinical trials, 1% of patients experienced skin and soft tissue reactions, including 0.3% who experienced Grade 3-4 reactions. Reactions may be delayed. Erythema, swelling, increased temperature, and pain worsened until 2-7 days after extravasation and resolved within 1-4 weeks of peak. Two patients (0.3%) developed extravasation reactions with secondary cellulitis, bullae, or exfoliation. Ensure adequate venous access prior to starting PADCEV and monitor for possible extravasation during administration. If extravasation occurs, stop the infusion and monitor for adverse reactions. Embryo-fetal toxicity PADCEV can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during PADCEV treatment and for 2 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with PADCEV and for 4 months after the last dose. ADVERSE REACTIONS Adverse reactions leading to discontinuation of PADCEV occurred in 35% of patients. The most common adverse reactions (≥2%) leading to discontinuation of PADCEV were PN (15%), rash (4.1%) and pneumonitis/ILD (2.3%). Adverse reactions leading to dose interruption of PADCEV occurred in 73% of patients. The most common adverse reactions (≥2%) leading to dose interruption of PADCEV were PN (22%), rash (16%), COVID‑19 (10%), diarrhea (5%), pneumonitis/ILD (4.8%), fatigue (3.9%), hyperglycemia (3.6%), increased ALT (3%) and pruritus (2.5%). Adverse reactions leading to dose reduction of PADCEV occurred in 42% of patients. The most common adverse reactions (≥2%) leading to dose reduction of PADCEV were rash (16%), PN (13%) and fatigue (2.7%). Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated monomethyl auristatin E exposure, which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors. Hepatic impairment Avoid the use of PADCEV in patients with moderate or severe hepatic impairment. For more information, please see the U.S. full Prescribing Information including BOXED WARNING for PADCEVhere. This release contains forward-looking information about Pfizer Oncology and PADCEV™(enfortumab vedotin) in combination with pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer, including their potential benefits, and plans to submit results from the Phase 3 EV-303 clinical trial for presentation at an upcoming medical congress and to share the Phase 3 EV-303 clinical trial results with the appropriate regulatory authorities to explore potential regulatory filings that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of PADCEV; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed with regulatory authorities in particular jurisdictions for any potential indication for PADCEV with pembrolizumab or as a single agent; whether and when any applications that may be pending or filed for PADCEV with pembrolizumab or as a single agent may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether PADCEV with pembrolizumab or as a single agent will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of PADCEV with pembrolizumab or as a single agent; whether the collaboration between Pfizer, Astellas and Merck will be successful; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer's business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned 'Risk Factors' and 'Forward-Looking Information and Factors That May Affect Future Results', as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available View source version on CONTACT: Pfizer Media Contact: [email protected] +1-212-733-1226 Pfizer Investor Contact: [email protected] +1-212-733-4848 Astellas Contact: Garrett Karaaziz [email protected] Corporate Communications +81-3-3244-3202 KEYWORD: UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC NEW YORK INDUSTRY KEYWORD: RESEARCH SURGERY GENETICS CLINICAL TRIALS BIOTECHNOLOGY HEALTH PHARMACEUTICAL SCIENCE ONCOLOGY SOURCE: Pfizer Inc. Copyright Business Wire 2025. PUB: 08/12/2025 05:30 AM/DISC: 08/12/2025 05:29 AM
Motor 1
3 hours ago
- Motor 1
Toyota Wants to Use Its New Gas Engines for Everything
Toyota is adamant that the internal combustion engine still has a bright future despite the rise of electric vehicles. The world's largest carmaker has reaffirmed its long-term commitment to ICE by partnering with fellow Japanese brands Subaru and Mazda on a new family of gas engines. Smaller and lighter four-cylinder units are touted as a 'game-changer solution' by the company's Chief Technology Officer, Hiroki Nakajima. We now know the Japanese automotive giant plans to use the upcoming 1.5- and 2.0-liter engines in nearly every conceivable type of powertrain. Toyota Europe Vice President of Product Strategy and Marketing Andrea Carlucci told Automotive News the new hardware's versatility is key: 'We are trying to optimize the new engine for any type of application, whether it's electric, hybrid, or hydrogen.' While the idea of a gas engine in an electric application might sound odd, a plausible scenario exists. Toyota is likely referring to extended-range electric vehicles (EREVs), where the combustion engine doesn't drive the wheels but instead serves solely as a generator to recharge the battery on the go. This setup allows the engine to run at optimal speeds for maximum efficiency. Examples include the BMW i3 REX, the Ramcharger, Mazda MX-30 , Scout's upcoming truck and SUV, and Nissan's models equipped with E-Power tech. Toyota has already announced plans to sell extended-range electric vehicles in China through its local joint venture with GAC, giving the Highlander SUV and Sienna minivan the EREV treatment. These models are expected to use a small engine that isn't mechanically connected to the wheels. Instead, propulsion will come exclusively from electric motors, with the engine serving only to extend range without abandoning gasoline entirely. Toyota achieved 41 percent thermal efficiency back in 2018 and could be aiming to improve that figure further. Its next-generation engines will run not only on fossil fuels, but also on biofuel, hydrogen, and synthetic fuel. Beyond full hybrids and EREVs, Toyota is also exploring long-range plug-in hybrids, with Carlucci estimating that 62 miles (100 kilometers) without sipping any gasoline represents the 'tipping point.' Confirmed engines include naturally aspirated and turbocharged 1.5-liter units, along with a larger 2.0-liter turbo. Efficiency won't be the only focus as the latter will also have a performance version for Gazoo Racing (GR) models, delivering up to 600 horsepower in race cars. New Toyota four-cylinder engines 33 Carlucci also discussed vehicle architectures: 'Everybody has taken an ICE platform and turned it into something that is electrified to some degree. So, why not conceive a platform that is EV-native and see how much we can adapt it to be used for a plug-in hybrid or a full-hybrid without sacrificing any of the new platform's strengths?' Of course, dedicated electric platforms are nothing new. Tesla is the obvious example, but there's also Volkswagen Group's MEB, Hyundai and Kia's E-GMP, and Mercedes' EVA, among others. Additionally, some EV-native platforms can also accommodate combustion engines, such as Stellantis' STLA Small, Medium, Large, and Frame. Scout's upcoming models fit this category, as will VW Group vehicles on the forthcoming Scalable Systems Platform (SSP) . Much like Toyota chairman Akio Toyoda, who has famously said EVs will never exceed a 30 percent market share, Carlucci maintains that electric cars are not the sole path to decarbonization. He argues for powertrain diversity, giving customers the freedom to choose: 'We will not push EVs in markets where there is no demand.' Toyota's New Engines: The New Toyota Engines Are Smaller but Better Toyota, Mazda, and Subaru Are Teaming up on New Combustion Engines Source: Automotive News Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
